A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease With a 6-Month Open Label Follow-Up Period.

Trial Profile

A 6-Month Prospective, Multi-Center, Double-Blind, Placebo-Controlled, Randomized, Adaptive-Trial-Design Study to Evaluate the Safety and Efficacy of 80mg b.i.d Ladostigil in Patients With Mild to Moderate Probable Alzheimer's Disease With a 6-Month Open Label Follow-Up Period.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Feb 2016

At a glance

  • Drugs Ladostigil (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Sponsors Avraham Pharmaceuticals
  • Most Recent Events

    • 22 May 2012 Inclusion and exclusion criteria amended and trial status is recruiting as reported by European Clinical Trials Database record.
    • 23 Feb 2012 Planned End Date changed from 1 Oct 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 23 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top